Biomarker and IVD pipeline
Scailyte’s clinical focus is to develop precision diagnostic applications for multimodal single cell data in oncology and women’s health by identifying biomarkers that outperform the current standard of care.
Establishing a precision diagnostics portfolio
Cutaneous T-cell lymphoma
First disease biomarker clinically validated:
Our trained AI demonstrated unprecedented accuracy in a blinded study
Cutaneous T cell lymphoma (CTCL) is a rare and severe skin cancer. In its initial stages CTCL shares similar symptoms to highly prevalent skin conditions such as atopic dermatitis (AD). Currently there is a lack of a definitive diagnostic test for CTCLs which means the disease is typically identified in advanced stages, once the patient’s immune system is compromised, or worse: altogether misdiagnosed. For the most aggressive form of CTCL, Sezary Syndrome, the 5 year survival rate is between 20–27%.
Scailyte is courageous. We’ve stepped up to the challenge by developing a precise, predictive and trustworthy diagnostic test.
Using our proprietary AI driven cell analytics pipeline, we identified CTCL- specific biomarkers that accurately diagnose CTCL with >90% specificity and sensitivity.
This powerful diagnostic test will enable early intervention, improve patient’s quality of life, reduce treatment costs and most importantly, save lives.